ethyl 6-(methoxymethyl)-5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-carboxylate | 1227157-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: ethyl 6-(methoxymethyl)-5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-carboxylate
• 英文别名: ethyl 6-(methoxymethyl)-5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridine-8-carboxylate；Ethyl 6-(methoxymethyl)-5-oxo-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine-8-carboxylate
• CAS: 1227157-60-9
• 化学式: C₁₇H₂₀N₂O₄
• 分子量: 316.357
• InChiKey: ZPLPMPHMFXXSIE-UHFFFAOYSA-N

物化性质

• 沸点：
  485.0±45.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 6-(methoxymethyl)-5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-carboxylate 在 lithium aluminium tetrahydride 、 水 、 氯化铵 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以94%的产率得到8-(hydroxymethyl)-6-(methoxymethyl)-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridin-5-(6H)one
  参考文献：
  名称：

  NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

  摘要：

  本发明涉及一种新型三环衍生物，具有高效的抑制聚(ADP-核糖)聚合酶（PARP）或其药用可接受盐的活性，以及其制备方法和含有该衍生物的药物组合物。本发明的三环衍生物通过抑制聚(ADP-核糖)聚合酶的活性，对于预防或治疗由过度PARP活性引起的疾病特别有效，包括神经病痛、神经退行性疾病、心血管疾病、糖尿病肾病、炎症性疾病、骨质疏松症和癌症。

  公开号：

  US20110218193A1
• 作为产物：
  描述：

  2-氯烟酸 在 三丁基膦 、 1,3-双(二苯基膦)丙烷 、 palladium diacetate 、 N,N-二甲基甲酰胺 草酰氯 、 potassium tert-butylate 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.5h， 生成 ethyl 6-(methoxymethyl)-5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-carboxylate
  参考文献：
  名称：

  NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

  摘要：

  本发明涉及一种新型三环衍生物，具有高效的抑制聚(ADP-核糖)聚合酶（PARP）或其药用可接受盐的活性，以及其制备方法和含有该衍生物的药物组合物。本发明的三环衍生物通过抑制聚(ADP-核糖)聚合酶的活性，对于预防或治疗由过度PARP活性引起的疾病特别有效，包括神经病痛、神经退行性疾病、心血管疾病、糖尿病肾病、炎症性疾病、骨质疏松症和癌症。

  公开号：

  US20110218193A1

文献信息

• Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
  申请人：Je Il Pharmaceutical Co., Ltd.

  公开号：US10464919B2

  公开（公告）日：2019-11-05

  The present invention relates to novel tricyclic derivative compounds, and more specifically to tricyclic derivative compounds, optical isomers thereof, racemates thereof, or pharmaceutically acceptable salts thereof, which have excellent activity against PARP-1, tankyrase-1 or tankyrase-2. The tricyclic derivative compounds, optical isomers thereof, racemates thereof or pharmaceutically acceptable salts thereof according to the present invention have inhibitory activity against PARP-1, tankyrase-1, or tankyrase-2, and thus can be effectively used for the prevention or treatment of neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, or cancer.

  本发明涉及新型三环衍生物化合物，更具体地说，涉及对PARP-1、tankyrase-1或tankyrase-2具有优异活性的三环衍生物化合物、其光学异构体、外消旋体或其药学上可接受的盐。根据本发明的三环衍生物化合物、其光学异构体、其外消旋物或其药学上可接受的盐对PARP-1、tankyrase-1或tankyrase-2具有抑制活性，因此可有效地用于预防或治疗神经性疼痛、神经退行性疾病、心血管疾病、糖尿病神经病变、炎症性疾病、骨质疏松症或癌症。
• TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：ONCONIC THERAPEUTICS INC.

  公开号：EP3312177B1

  公开（公告）日：2021-04-14
• Tricyclic Derivative Compound, Method for Preparing Same, and Pharmaceutical Composition Comprising Same
  申请人：Je Il Pharmaceutical Co., Ltd.

  公开号：US20180162834A1

  公开（公告）日：2018-06-14

  The present invention relates to novel tricyclic derivative compounds, and more specifically to tricyclic derivative compounds, optical isomers thereof, racemates thereof, or pharmaceutically acceptable salts thereof, which have excellent activity against PARP-1, tankyrase-1 or tankyrase-2. The tricyclic derivative compounds, optical isomers thereof, racemates thereof or pharmaceutically acceptable salts thereof according to the present invention have inhibitory activity against PARP-1, tankyrase-1, or tankyrase-2, and thus can be effectively used for the prevention or treatment of neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, or cancer.
• US8815891B2
  申请人：——

  公开号：US8815891B2

  公开（公告）日：2014-08-26
• [EN] TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] COMPOSÉ DÉRIVÉ TRICYCLIQUE, SON PROCÉDÉ DE PRÉPARATION, ET COMPOSITION PHARMACEUTIQUE LE CONTENANT<br/>[KO] 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
  申请人：JE IL PHARMACEUTICAL CO LTD

  公开号：WO2016200101A2

  公开（公告）日：2016-12-15

  본 발명은 신규한 트리사이클릭 유도체 화합물에 관한 것으로서, 보다 상세하게는 우수한 PARP-1. 탄키라제-1 또는 탄키라제-2 저해 활성을 갖는 트리사이클릭 유도체 화합물, 이의 광학이성질체, 이의 라세미체 또는 이의 약학적으로 허용가능한 염에 관한 것이다. 본 발명에 따른 트리사이클릭 유도체 화합물, 이의 광학이성질체, 이의 라세미체 또는 이의 약학적으로 허용 가능한 염은 PARP-1. 탄키라제-1 또는 탄키라제-2 저해 활성을 통하여 신경병리성 동통, 신경퇴화질환, 심혈관계 질환, 당뇨로 인한 신경병증, 염증성 질환, 골다공증 또는 암의 예방 또는 치료에 유용하게 사용될 수 있다.